QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA

Thursday, July 28, 2016 General News
Email Print This Page Comment bookmark
Font : A-A+

HILDEN, Germany and GERMANTOWN, Maryland, July 27, 2016

/PRNewswire/ --

PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in

prenatal testing and cancer research

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new PAXgeneŪ Blood ccfDNA Tube* for venous whole blood collection and room temperature stabilization of in-vivo circulating cell-free DNA (ccfDNA) profiles.

Together with the QIAamp Circulating Nucleic Acid Kit - the gold standard in manual extraction of circulating cell-free DNA - and upcoming new automated ccfDNA isolation on the QIAsymphony, PAXgene Blood ccfDNA builds a fully integrated and complete standardized system covering all pre-analytical workflow steps from blood collection, stabilization, transport, storage and isolation of high quality ccfDNA.

The new system contains a unique non-crosslinking reagent in the collection tube that ensures DNA remains unmodified. It prevents post-collection release of genomic DNA from white blood cells - resulting in improved ccfDNA yield recovery with less background DNA. A minimized release of contents of ruptured red blood cells into blood plasma (hemolysis) enables a maximized plasma recovery, particularly critical in cancer research. Combined with the proven plastic BD VacutainerŪ Tube technology, customers will benefit from consistent blood draws and no more glass tube breakage during the workflow.

Click here for full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={D143ECCD-F324-45A1-BFEE-C9BC695F6592}&lang=en

PreAnalytiX

Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email: [email protected] www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com

Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: [email protected] ir.qiagen.com

SOURCE QIAGEN N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook